We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
President Biden submitted his fiscal 2023 budget request yesterday, seeking an $8.4 billion budget for the FDA for fiscal year 2023, a whopping 34 percent increase from fiscal 2022. Read More
Three antibodies directed at interleukins — inflammatory proteins associated with a number of skin disorders — posted positive phase 3 results and were touted at the annual meeting of the American Academy of Dermatology (AAD). Read More
The price of U.S. cancer drugs keeps climbing despite market competition, while the costs of the same drugs have stayed relatively flat or have actually decreased in Germany and Switzerland. Read More
The FDA has told MEI Pharma and Kyowa Kirin that they will need to provide more than results from a single-arm phase 2 study on their oral lymphoma drug candidate zandelisib to have it considered for the agency’s accelerated approval pathway. Read More
The U.S. government is pulling GlaxoSmithKline’s and Vir Technology’s investigational monoclonal antibody for COVID-19 from certain states where cases of the new subvariant of Omicron, BA.2, are high, as tests have shown that the treatment isn’t effective against the new strain. And the FDA has amended sotrovimab’s Emergency Use Authorization (EUA) accordingly. Read More